Mizuho Senior Biotech Analyst Salim Syed highlights key companies in the news he covers heading into the new year
BiotechTV - News
00:00
Guidance and IP timing for tafamidis
Salim doubts full-year 2026 guidance from Bridge and summarizes the uncertain court schedule on tafamidis IP.
Play episode from 05:25
Transcript
